Lilly agrees acquisition of Merida Biosciences in deal worth up to $2.875bn
Lilly’s planned acquisition of Merida Biosciences adds an antibody-engineering platform designed to selectively remove disease-causing antibodies while preserving normal immune function.
Eli Lilly has entered into a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and contingent milestone payments.
The transaction strengthens Lilly’s immunology portfolio and brings in Merida’s lead programme MER511, which has shown early Phase 1 reductions in pathogenic thyroid-stimulating antibodies.
Field | Content |
Alert Type | Deal |
Companies | Eli Lilly and Company; Merida Biosciences |
Deal Type | Acquisition |
Asset or Company | Merida Biosciences |
Therapy Area(s) | Autoimmune and allergic diseases |
Technology or Modality | Antibody-engineering platform designed to selectively degrade pathogenic autoantibodies |
Lead Programme | MER511 |
Deal Value | Up to $2.875 billion in cash, including an upfront payment and contingent milestone payments |
Geography | United States |
What Happened | On 31 August 2026, Eli Lilly and Merida Biosciences announced a definitive agreement under which Lilly will acquire Merida for up to $2.875 billion in cash. |
Why It Matters | The acquisition expands Lilly's immunology capabilities with a platform designed to target and remove disease-causing antibodies while preserving normal immune function. |
Supporting Evidence | Initial Phase 1 data for MER511 showed robust reductions in pathogenic thyroid-stimulating antibodies with a favourable initial safety profile. |
Supporting Context | Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies implicated in a range of immune-mediated diseases. |
Strategic Rationale | Lilly gains a precision immunology platform and pipeline that could complement its existing presence in autoimmune and allergic diseases. |
Potential Impact | If successfully developed, Merida's programmes could provide new therapeutic approaches for immune-mediated conditions driven by pathogenic antibodies. |
Key Takeaway | Lilly is investing up to $2.875 billion to acquire Merida and add a differentiated antibody-degradation platform to its immunology portfolio. |
What to Watch | Regulatory approvals, expected transaction completion in the fourth quarter of 2026 and further clinical development of MER511. |
Primary Source | Eli Lilly and Company |
Relevant Date | 31 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare